Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Change in Cash (2016 - 2025)

Rocket Pharmaceuticals' Change in Cash history spans 10 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 98.38% year-over-year to $1.6 million; the TTM value through Dec 2025 reached -$86.1 million, down 179.93%, while the annual FY2025 figure was -$86.1 million, 179.93% down from the prior year.
  • Change in Cash for Q4 2025 was $1.6 million at Rocket Pharmaceuticals, down from $43.1 million in the prior quarter.
  • Across five years, Change in Cash topped out at $180.6 million in Q3 2023 and bottomed at -$169.8 million in Q4 2023.
  • The 5-year median for Change in Cash is -$15.0 million (2021), against an average of -$11.0 million.
  • The largest annual shift saw Change in Cash crashed 969.48% in 2021 before it soared 1877.56% in 2023.
  • A 5-year view of Change in Cash shows it stood at -$12.9 million in 2021, then plummeted by 334.02% to -$56.2 million in 2022, then crashed by 202.23% to -$169.8 million in 2023, then skyrocketed by 157.75% to $98.0 million in 2024, then tumbled by 98.38% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Change in Cash are $1.6 million (Q4 2025), $43.1 million (Q3 2025), and -$17.0 million (Q2 2025).